Barrett & Company Inc. Has $76,000 Position in Masimo Co. (NASDAQ:MASI)

Barrett & Company Inc. trimmed its stake in shares of Masimo Co. (NASDAQ:MASI) by 50.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 567 shares of the medical equipment provider’s stock after selling 566 shares during the quarter. Barrett & Company Inc.’s holdings in Masimo were worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Thrivent Financial for Lutherans lifted its position in shares of Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after purchasing an additional 360,497 shares during the period. Point72 Asset Management L.P. boosted its position in Masimo by 107.8% during the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock valued at $85,347,000 after acquiring an additional 351,523 shares during the last quarter. Bamco Inc. NY acquired a new stake in Masimo during the 1st quarter worth about $50,781,000. Farallon Capital Management LLC raised its position in shares of Masimo by 13.6% in the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after acquiring an additional 177,914 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Masimo by 45.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock valued at $66,201,000 after purchasing an additional 165,257 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Friday, September 20th. Piper Sandler reiterated an “overweight” rating on shares of Masimo in a report on Friday, October 18th. Finally, BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has an average rating of “Moderate Buy” and a consensus target price of $145.33.

Masimo Stock Up 1.0 %

MASI traded up $1.41 during midday trading on Monday, reaching $140.74. 42,085 shares of the company were exchanged, compared to its average volume of 674,429. Masimo Co. has a one year low of $75.36 and a one year high of $153.93. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. The company’s fifty day moving average price is $127.36 and its 200 day moving average price is $125.13. The company has a market cap of $7.48 billion, a price-to-earnings ratio of 94.78 and a beta of 0.99.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The business had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. During the same period in the prior year, the firm posted $0.62 EPS. Masimo’s quarterly revenue was up 9.0% compared to the same quarter last year. As a group, analysts expect that Masimo Co. will post 3.88 EPS for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.